GlassScriptPhysician profile
Lillian Frances Lien
NPI 1033293188
$3,230.56
in general payments reported to CMS, 2019-2025
23 companies · $49.60 in 2025
The $49.60 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $53.28 · 2021: $500 · 2022: $848 · 2023: $251 · 2024: $328 · 2025: $49.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $497.60 | 2019-2022 | |
| Amgen INC. | $406.18 | 2019-2024 | Prolia, Evenity |
| Dexcom, INC. | $394.98 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $266.59 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $229.12 | 2019-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $222.76 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $221.64 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $167.35 | 2019-2021 | |
| Insulet Corporation | $133.72 | 2019-2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.67 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $82.57 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Medtronic Minimed, INC. | $78.00 | 2019 | |
| Corcept Therapeutics | $70.47 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.94 | 2021-2022 | |
| Abbvie INC. | $59.48 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $48.19 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $43.40 | 2019-2020 | |
| Pfizer INC. | $32.20 | 2019-2021 | |
| Shire North American Group INC | $28.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.82 | 2019 | |
| Kyowa Kirin, INC. | $21.41 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $19.98 | 2019 | |
| Nevro Corp. | $17.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Lien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.